HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies.
HER2
PD-1/PD-L1
antibody-drug conjugate
chemotherapy
clinical trials
gastric cancer
immunotherapy
novel therapies
trastuzumab
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Jul 2023
13 Jul 2023
Historique:
received:
02
06
2023
revised:
05
07
2023
accepted:
07
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Gastric cancer is an aggressive disease with increasing global incidence in recent years. Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10-20% of gastric cancers. The implementation of targeted therapy against HER2 as part of the standard of care treatment in metastatic disease has improved the prognosis of this subset of patients. However, gastric cancer still has high mortality rates and urgently requires new treatment strategies. The combination of immunotherapy with HER2-targeted therapies has shown synergistic effects in preclinical models, this being the rationale behind exploring this combination in clinical trials in locally advanced and metastatic settings. Additionally, the irruption of antibody-drug conjugates and other novel HER2-targeted agents has led to the development of numerous clinical trials showing promising results. This review presents the molecular mechanisms supporting the use of HER2-targeted drugs in combination with immunotherapy and provides an overview of the therapeutic scenario of HER2-positive disease. We focus on the role of immunotherapy but also summarize emerging therapies and combinations under clinical research that may change the standard treatment in HER-2 positive disease in the future.
Identifiants
pubmed: 37511163
pii: ijms241411403
doi: 10.3390/ijms241411403
pmc: PMC10380453
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Immunoconjugates
0
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Mol Cancer Ther. 2018 Jul;17(7):1494-1503
pubmed: 29703841
Clin Cancer Res. 2013 Mar 15;19(6):1476-86
pubmed: 23363817
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Cancer Metastasis Rev. 2015 Mar;34(1):157-64
pubmed: 25712293
Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):700-13
pubmed: 24618998
J Clin Oncol. 2017 Feb;35(4):446-464
pubmed: 28129524
J Clin Oncol. 2016 Feb 10;34(5):443-51
pubmed: 26628478
Lancet Oncol. 2017 May;18(5):640-653
pubmed: 28343975
J Clin Oncol. 2022 Nov 10;40(32):3750-3761
pubmed: 35709415
Nanomaterials (Basel). 2015 Jun 09;5(2):1004-1021
pubmed: 28347048
Cancer Res. 2016 Mar 15;76(6):1517-27
pubmed: 26759238
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
BMC Cancer. 2019 Jan 8;19(1):38
pubmed: 30621632
J Clin Oncol. 2013 Dec 10;31(35):4438-44
pubmed: 24190112
Clin Cancer Res. 2016 Jul 1;22(13):3249-59
pubmed: 26842237
Eur J Cancer. 2011 Oct;47(15):2306-14
pubmed: 21742485
Nat Med. 2015 May;21(5):449-56
pubmed: 25894828
Cancer Med. 2018 Jun;7(6):2612-2620
pubmed: 29673110
J Clin Med Res. 2021 Apr;13(4):222-229
pubmed: 34007360
Dig Liver Dis. 2022 Oct;54(10):1419-1427
pubmed: 35123909
Pathol Oncol Res. 2020 Oct;26(4):2225-2235
pubmed: 32372174
J Gastrointest Oncol. 2014 Feb;5(1):25-35
pubmed: 24490040
Cancer Treat Rev. 2022 May;106:102395
pubmed: 35468539
Nature. 2021 Dec;600(7890):727-730
pubmed: 34912120
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
pubmed: 11252954
Lancet Oncol. 2020 Jun;21(6):821-831
pubmed: 32437664
Br J Cancer. 2021 Feb;124(3):595-603
pubmed: 33100329
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
Clin Cancer Res. 2013 Feb 1;19(3):598-609
pubmed: 23095323
J Gastrointest Oncol. 2016 Oct;7(5):750-762
pubmed: 27747089
Head Neck Pathol. 2013 Jun;7(2):113-21
pubmed: 23179191
World J Gastroenterol. 2012 Mar 7;18(9):971-8
pubmed: 22408358
Clin Pathol. 2022 May 25;15:2632010X221096378
pubmed: 35651850
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
World J Gastroenterol. 2016 Mar 21;22(11):3069-77
pubmed: 27003986
Sci Transl Med. 2015 Nov 25;7(315):315ra188
pubmed: 26606967
Oncology. 2017;93(6):387-394
pubmed: 28910818
J Natl Compr Canc Netw. 2022 Feb;20(2):167-192
pubmed: 35130500
Oncoimmunology. 2018 Apr 24;7(8):e1457602
pubmed: 30221053
Future Oncol. 2021 Apr;17(10):1155-1164
pubmed: 33263418
Oncoimmunology. 2015 Oct 29;5(4):e1100790
pubmed: 27141382
Endosc Int Open. 2015 Apr;3(2):E165-70
pubmed: 26135662
Oncotarget. 2016 May 31;7(22):32318-28
pubmed: 27086918
Mol Pharm. 2011 Dec 5;8(6):2101-41
pubmed: 21974749
JAMA Oncol. 2022 Aug 1;8(8):1150-1158
pubmed: 35737383
Theranostics. 2019 Jul 28;9(19):5610-5625
pubmed: 31534506
Curr Oncol. 2022 Mar 02;29(3):1559-1574
pubmed: 35323331
Immunol Lett. 2012 Feb 29;142(1-2):78-82
pubmed: 22138406
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Future Oncol. 2022 Sep;18(29):3255-3266
pubmed: 36000541
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13866-71
pubmed: 11698646
Gan To Kagaku Ryoho. 2017 Oct;44(10):883-885
pubmed: 29066684
J Gastrointest Surg. 2015 Sep;19(9):1565-71
pubmed: 26179664
Acta Pharmacol Sin. 2022 Mar;43(3):672-680
pubmed: 33990766
Annu Rev Immunol. 2005;23:515-48
pubmed: 15771580
J Clin Oncol. 2010 Sep 20;28(27):e471-2; author reply e473
pubmed: 20585098
Gastroenterology Res. 2019 Dec;12(6):275-282
pubmed: 31803306
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
Front Pharmacol. 2018 May 22;9:536
pubmed: 29910728
Gut. 2017 Nov;66(11):1878-1880
pubmed: 28348197
J Natl Cancer Inst. 1986 Nov;77(5):1047-52
pubmed: 3464796
J Gastrointest Oncol. 2022 Apr;13(2):548-558
pubmed: 35557572
Sci Rep. 2016 Jul 01;6:28910
pubmed: 27363678
Lancet Oncol. 2014 Jan;15(1):78-86
pubmed: 24332238
J Cancer. 2012;3:137-44
pubmed: 22481979
Genes Cancer. 2013 May;4(5-6):187-95
pubmed: 24069506
Oncotarget. 2018 Jun 1;9(42):26787-26799
pubmed: 29928485
Lancet. 2023 May 20;401(10389):1655-1668
pubmed: 37068504
Gut. 2015 Nov;64(11):1721-31
pubmed: 25385008
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Mol Cancer Ther. 2006 Nov;5(11):2666-75
pubmed: 17121913
J Clin Oncol. 2010 Oct 1;28(28):4390-9
pubmed: 20697078
Nat Commun. 2022 Oct 28;13(1):6274
pubmed: 36307405
Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8
pubmed: 11597398
Cancer Cell. 2010 Aug 9;18(2):160-70
pubmed: 20708157
Gut. 2014 Feb;63(2):236-43
pubmed: 23580779
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7142-7
pubmed: 21482773
Cancer Res. 2014 Oct 1;74(19):5561-71
pubmed: 25228655
Cancer Lett. 2018 Aug 28;430:47-56
pubmed: 29746929
Support Care Cancer. 2022 Apr;30(4):3215-3224
pubmed: 34973098
Int J Mol Sci. 2020 Jun 04;21(11):
pubmed: 32512697
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
J Chin Med Assoc. 2014 Jul;77(7):345-53
pubmed: 24907022
J Immunol. 2003 Aug 15;171(4):2161-9
pubmed: 12902523
BMC Cancer. 2019 May 24;19(1):494
pubmed: 31126258
J Control Release. 2010 Sep 15;146(3):264-75
pubmed: 20385184
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):591-603
pubmed: 29579788
J Clin Invest. 2012 Mar;122(3):1066-75
pubmed: 22326955
Dig Dis Sci. 2006 Aug;51(8):1371-9
pubmed: 16868827
Oncoimmunology. 2019 Aug 26;8(11):e1648171
pubmed: 31646095
Gastric Cancer. 2023 Jan;26(1):123-131
pubmed: 36066725
J Clin Oncol. 2000 Jun;18(11):2201-9
pubmed: 10829039
Oncotarget. 2016 Jun 7;7(23):34824-31
pubmed: 27166187
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Oncotarget. 2015 Jun 10;6(16):14209-19
pubmed: 25895031
Gastric Cancer. 2016 Apr;19(2):553-560
pubmed: 25987463
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Ann Oncol. 2022 Oct;33(10):1005-1020
pubmed: 35914639
Cancers (Basel). 2022 Feb 18;14(4):
pubmed: 35205802
J Clin Oncol. 2014 Jul 1;32(19):2039-49
pubmed: 24868024
Sci Adv. 2019 Dec 11;5(12):eaay1357
pubmed: 31844672
Science. 1986 Jun 27;232(4758):1644-6
pubmed: 3012781
Hum Pathol. 2016 Sep;55:182-9
pubmed: 27260946
Asian Pac J Cancer Prev. 2022 Apr 01;23(4):1433-1444
pubmed: 35485706
J Gastrointest Oncol. 2012 Sep;3(3):251-61
pubmed: 22943016
Eur J Cancer. 2021 Mar;145:158-167
pubmed: 33485079
Oncol Lett. 2016 May;11(5):2959-2964
pubmed: 27123046
Am J Clin Pathol. 2019 Jul 5;152(2):169-176
pubmed: 30984969
World J Gastroenterol. 2016 May 21;22(19):4619-25
pubmed: 27217694
Cell Mol Biol (Noisy-le-grand). 2010 Sep 11;56 Suppl:OL1366-72
pubmed: 20937224
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Cancer Res. 2017 Oct 1;77(19):5374-5383
pubmed: 28819024
Ann Oncol. 2008 Sep;19(9):1523-9
pubmed: 18441328
World J Gastroenterol. 2014 May 21;20(19):5679-84
pubmed: 24914328
Lancet. 2018 Jul 14;392(10142):123-133
pubmed: 29880231
Lancet Oncol. 2014 Feb;15(2):e58-68
pubmed: 24480556
Biochem Biophys Res Commun. 2018 Feb 26;497(1):394-400
pubmed: 29438713
Ann Oncol. 2011 Dec;22(12):2604-2609
pubmed: 21415237
World J Gastroenterol. 2013;19(14):2171-8
pubmed: 23599643
Jpn J Clin Oncol. 2015 Nov;45(11):1082-6
pubmed: 26355164
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
J Biol Chem. 2021 Dec;297(6):101420
pubmed: 34798072
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686
Int J Cancer. 2021 Sep 15;149(6):1322-1331
pubmed: 34019698
Eur J Cancer Prev. 2017 Jul;26(4):357-364
pubmed: 27275735
Nat Rev Clin Oncol. 2016 Jun;13(6):348-60
pubmed: 26925958
Cancer Imaging. 2018 Nov 9;18(1):42
pubmed: 30413174
Ann Oncol. 2009 Sep;20(9):1529-1534
pubmed: 19474114
Breast Cancer Res. 2010;12(4):R48
pubmed: 20626886
Blood. 2010 Aug 19;116(7):1124-31
pubmed: 20472834